Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

February 14, 2024

Conditions
Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Interventions
DRUG

Linperlisib

"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."

Trial Locations (2)

Unknown

Zhoukou Central Hospital, Zhoukou

Regenerative Medicine Center, Tianjin

All Listed Sponsors
collaborator

YL-Pharma

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER